Bhola Rama, MD
Cardiovascular Disease · Marion, OHNPI 1306804349
Payments from drug & device makers
Across 912 payments — averaging $2282.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$753K
- Boehringer Ingelheim Pharma GmbH & Co.kg$241K
- Boehringer Ingelheim International GmbH$202K
- Genentech, Inc.$192K
- Bayer$155K
- Amgen$150K
- plus $389K from 14 others
Across 57 payments — averaging $728.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vifor (international) Ltd.$40K
- Eli Lilly$1K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 29 | $753,121 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 65 | $241,031 |
| Boehringer Ingelheim International GmbH | 478 | $202,463 |
| Genentech, Inc. | 11 | $192,073 |
| Bayer | 57 | $154,642 |
| Amgen | 23 | $149,703 |
| AstraZeneca | 7 | $122,525 |
| Boehringer Ingelheim | 7 | $104,474 |
| Eli Lilly | 3 | $67,161 |
| Astrazeneca UK Limited | 2 | $47,372 |
| Alnylam Pharmaceuticals Inc. | 209 | $45,125 |
| Boehringer Ingelheim France S.a.s. | 5 | $699 |
| Boehringer Ingelheim Canada Ltd.ltee | 6 | $616 |
| Merck | 3 | $526 |
| Medtronic | 1 | $56 |
| Pfizer | 2 | $34 |
| Lantheus Medical Imaging, Inc. | 1 | $33 |
| Biotronik Inc. | 1 | $21 |
| Amarin Pharma, Inc. | 1 | $15 |
| Biomerieux Inc | 1 | $14 |
How this compares
$2,081,703 in reported general payments places this provider in the 95th percentile of 827 cardiovascular disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Marion
- Samir KapadiaCleveland$11.1M
- Steven NissenCleveland$5.3M
- Milind DesaiCleveland$5M
- Abraham LincoffCleveland$3.6M
- Carlos HubbardCleveland$3.1M
- Guilherme AttizzaniCleveland$2.8M
- Wai Hong TangCleveland$2.2M
- Mazen HannaCleveland$1.6M
- Akber MohammedSpringfield$1.6M
- Ademola AbioseElyria$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.